Aceragen, Inc.
Aceragen, Inc., a prominent biotechnology firm headquartered in the United States, is dedicated to advancing innovative therapies for rare diseases. Founded in 2018, the company has quickly established itself in the biopharmaceutical industry, focusing on the development of transformative treatments that address unmet medical needs. With a strong operational presence across key regions in the US, Aceragen is committed to harnessing cutting-edge science to create unique products that enhance patient outcomes. Their core offerings include novel therapeutics designed to target specific genetic disorders, setting them apart in a competitive market. Recognised for its rapid growth and commitment to research excellence, Aceragen continues to make significant strides in the biotechnology landscape, positioning itself as a leader in the quest for effective solutions for rare diseases.
DitchCarbon Score
How does Aceragen, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aceragen, Inc.'s score of 23 is lower than 77% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Aceragen, Inc.'s reported carbon emissions
Aceragen, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of data suggests that Aceragen may not have established formal commitments to reduce its carbon footprint or engage in industry-standard climate initiatives such as the Science Based Targets initiative (SBTi) or the Carbon Disclosure Project (CDP). As a result, Aceragen's climate commitments remain unclear, and the company does not appear to inherit any emissions data or targets from a parent organisation. Without specific emissions data or reduction initiatives, it is challenging to assess the company's environmental impact or its alignment with broader climate goals within the biotechnology sector.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aceragen, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
